Marker Therapeutics (MRKR) Debt Ratio (2010 - 2022)

Marker Therapeutics (MRKR) posted quarterly Debt Ratio of 0.07 for Q4 2022, down 40.87% quarter-over-quarter from 0.12 in Q3 2022.

Marker Therapeutics (MRKR) Debt Ratio (2010 - 2022) Analysis & Trends

Marker Therapeutics (MRKR) has reported Debt Ratio for 7 consecutive years, with 0.07 the latest figure, recorded in Q4 2022.

In Q4 2022, Debt Ratio changed N/A year-over-year to 0.07; the TTM figure through Dec 2022 stood at 0.07 (changed N/A YoY), while the FY2022 annual figure was 0.07, changed N/A from the prior year.
Debt Ratio fell to 0.07 in Q4 2022 per MRKR's latest filing, from 0.12 in the prior quarter.
Across five years, Debt Ratio topped out at 0.15 in Q2 2022 and bottomed at 0.07 in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	0.05
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	0.03
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Marker Therapeutics	27.04 Mn	15.11 Mn	-	-

Download Data